Challenges of data sharing: valuable but costly?
Ian D Davis
The Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2017
Awarded by Australian National Health and Medical Research Council
I am supported by an Australian National Health and Medical Research Council Practitioner Fellowship (APP1102604). I am a member of several industry advisory boards, for which remuneration is paid to the Australian and New Zealand Urogenital and Prostate Cancer Trials Group, of which I am an unpaid director and chair: Pfizer renal cell carcinoma advisory board (chair from 2009); Novartis advisory board; Bristol-Myers Squibb ipilimumab and anti-PD1 advisory boards; Sanofi Jevtana advisory board; Astellas oncology portfolio advisory board (chair from 2015); Bayer Nexavar advisory board (chair from 2015); Roche genitourinary cancers advisory board and WO30070 study steering committee; and AstraZeneca IO advisory board. I am also an unpaid director and board member of the Clinical Oncology Society of Australia (COSA).